The complaint claims that Ardelyx failed to disclose significant payer-related hurdles, including stringent prior authorization and step-edit requirements. These barriers allegedly hindered patient access and slowed new-patient starts, ultimately suppressing the growth of the company’s core products. According to the lawsuit, these omissions resulted in the company overstating its commercial outlook during the specified period.
Ardelyx Faces Class Action Lawsuit Over Alleged Misleading Statements
Investors who purchased Ardelyx, Inc. securities between January 13, 2025, and August 6, 2026, are now the focus of a class action lawsuit. The filing, led by Bronstein, Gewirtz & Grossman, LLC, alleges the company misled shareholders regarding the commercial performance and market access of its drugs, XPHOZAH and IBSRELA.
Investors wishing to participate in the litigation have until November 16, 2026, to request appointment as lead plaintiff. Peretz Bronstein, founding partner of the law firm, noted that the action aims to restore capital and ensure corporate accountability. Affected parties can review the complaint or contact firm representatives Peretz Bronstein or Nathan Miller at 917-590-0911 for further details on the proceedings.
Comments (0)
No comments yet. Be the first!